Pearl Steinzor

Tiago Biachi de Castria, MD, PhD, associate member in the Department of Gastrointestinal Oncology at Moffitt Cancer Center, discusses how precision medicine tools have aided oncologists in treating patients with solid tumors, while reducing overall toxicity.

This year’s most-read asthma articles included the impact of extreme weather events, neighborhood determinants of health, and other risk factors for asthma exacerbations.

Posters presented at the American Society of Hematology Annual Meeting and Exposition identified factors associated with reducing risk and improving survival in patients with polycythemia vera (PV).

Our top coverage from this year’s Revolutionizing Atopic Dermatitis (RAD) conference highlighted the evolving therapy landscape for patients with AD.

Growing misinformation around COVID-19 vaccines may have resulted in changes in parents’ trust in vaccines.

Mona Shahriari, MD, assistant clinical professor of dermatology at Yale University and associate director of clinical trials at Central Connecticut Dermatology, discusses how dermatologists and clinicians can work towards increasing diversity and inclusion in treating patients with skin of color with plaque psoriasis.

A phase 4 study found severe asthma can be controlled using biologic therapies, without the addition of high-dose inhaled steroids.

In this podcast, Sonny Goyal, chief strategy officer at Blue Cross and Blue Shield of North Carolina, discusses recent value-based initiatives to support patients and reduce overall cost of care.

Polycythemia vera (PV) therapy should aim to identify cardiovascular risk factors, according to one review.

Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.

Given its growing significance in health care, there is an increasing need for digital research ethics and appropriate consent methods, according to one study.

Increased options and strong demand resulted in record-breaking 2024 enrollment.

Two posters presented at the 2023 Fall Clinical Dermatology Conference examined patient demographics, clinical characteristics, and outcomes in patients with plaque psoriasis treated with tapinarof cream.

Ruben A. Mesa, MD, president and executive director of Atrium Health Levine Cancer Institute and Atrium Health Wake Forest Baptist Comprehensive Cancer Center, discusses how value-based care teams can collaborate to ensure diversity and inclusion in clinical trials.

If finalized, these proposals will generally take effect on January 1, 2025, unless otherwise noted.

Desmoid tumors are noncancerous growths that appear in connective tissue, most often on the arms, legs, and abdomen. Aggressive tumors must be treated with surgery, radiation, or chemotherapy to keep them from growing into nearby organs, which can make them life threatening. They can cause pain and disfigurement, and they can reduce functioning and quality of life.

Triple therapy may improve asthma symptoms, particularly among patients requiring systemic corticosteroids to treat severe exacerbations, a study finds.

Posters presented at ACAAI 2023 Annual Scientific Congress examined dupilumab use in children with moderate-to-severe asthma and in the presence of elevated type 2 biomarkers.

Bevey Miner, executive vice president of health care strategy and policy, Consensus Cloud Solutions, discusses the importance of incorporating structured data into digital health policy to improve the speed and efficiency of shared information across multiple health settings.

A meta-analysis highlights the potential of influenza vaccination as an adjunctive strategy in reducing cardiovascular disease.

Alyson Moadel-Robblee, PhD, deputy director of community engagement and cancer health equity at Montefiore Einstein Comprehensive Cancer Center, discussed the center's evolving patient distress screening process and the Bronx Oncology Living Daily support program for patients with cancer.

A phase 3 trial in symptomatic and anemic patients with myelofibrosis (MF) met its primary end point, seeing a significant symptom reduction at 24 weeks with momelotinib vs danazol.

More than 77,000 additional doses of nirsevimab-alip will be distributed for respiratory syndactyl virus (RSV) immunization in infants.

Repotrectinib achieved a high objective response rate and durable response in the pivotal TRIDENT-1 trial.

Although telehealth is broadly accepted as a mode of cancer rehabilitation, accessibility and in-person challenges exist.

A recent study sheds light on issues surrounding the system's functionality, transparency, and responsiveness.

Ruben A. Mesa, MD, president and executive director of Atrium Health Levine Cancer Institute and Atrium Health Wake Forest Baptist Comprehensive Cancer Center, discusses key challenges and opportunities for improving cancer care among rural and minority patients.

Posters presented at ACAAI 2023 Annual Scientific Congress assessed digital health tools to improve asthma self-management.

Two posters presented at the 2023 Fall Clinical Dermatology Conference assessed phase 4 study findings on tildrakizumab in patients with moderate to severe plaque psoriasis.

Posters presented at the 2023 Fall Clinical Dermatology Conference evaluated how label warnings may affect new treatment initiation and real-word switching patterns for patients starting risankizumab.